A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

NCT06306339 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Rheumatoid Arthritis

Interventions

DRUG: Burfiralimab
DRUG: SOC (Standard of care)
DRUG: Placebo

Sponsor

ImmuneMed, Inc.